

Neutrophil Elastase Activity Is Associated with Exacerbations of Bronchiectasis

American Journal of Respiratory and Critical Care Medicine
195, 1384-1393

DOI: [10.1164/rccm.201605-1027oc](https://doi.org/10.1164/rccm.201605-1027oc)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Sputum Neutrophil Elastase as a Biomarker for Disease Activity in Bronchiectasis. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 1289-1291.	2.5	8
2	The Role of Neutrophil Elastase Inhibitors in Lung Diseases. Chest, 2017, 152, 249-262.	0.4	158
3	Health-related quality of life questionnaires in bronchiectasis: the simplest way to quantify complexity. European Respiratory Journal, 2017, 49, 1700208.	3.1	4
4	An update on pediatric bronchiectasis. Expert Review of Respiratory Medicine, 2017, 11, 517-532.	1.0	25
5	The challenge of defining exacerbation in bronchiectasis. European Respiratory Journal, 2017, 49, 1700700.	3.1	2
6	Bronchiectasis: Phenotyping a Complex Disease. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2017, 14, S12-S18.	0.7	26
7	Patient participation in ERS guidelines and research projects: the EMBARC experience. Breathe, 2017, 13, 194-207.	0.6	20
8	European Respiratory Society guidelines for the management of adult bronchiectasis. European Respiratory Journal, 2017, 50, 1700629.	3.1	788
9	The European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC): experiences from a successful ERS Clinical Research Collaboration. Breathe, 2017, 13, 180-192.	0.6	34
10	Profile of the ProAxis active neutrophil elastase immunoassay for precision medicine in chronic respiratory disease. Expert Review of Molecular Diagnostics, 2017, 17, 875-884.	1.5	10
11	The respiratory threat posed by multidrug resistant <i>G</i> -negative bacteria. Respiriology, 2017, 22, 1288-1299.	1.3	84
13	Role of Translocator 18 KDa Ligands in the Activation of Leukotriene B4 Activated G-Protein Coupled Receptor and Toll Like Receptor-4 Pathways in Neutrophils. Frontiers in Pharmacology, 2017, 8, 766.	1.6	6
14	Targets of Neutrophil Influx and Weaponry: Therapeutic Opportunities for Chronic Obstructive Airway Disease. Journal of Immunology Research, 2017, 2017, 1-13.	0.9	20
15	Neutrophil elastase in bronchiectasis. Respiratory Research, 2017, 18, 211.	1.4	75
16	Bronchiectasis: new therapies and new perspectives. Lancet Respiratory Medicine, 2018, 6, 715-726.	5.2	147
17	Dipeptidyl Peptidase 1 Inhibitor AZD7986 Induces a Sustained, Exposure-Dependent Reduction in Neutrophil Elastase Activity in Healthy Subjects. Clinical Pharmacology and Therapeutics, 2018, 104, 1155-1164.	2.3	49
18	Bronchiectasis update. Current Opinion in Infectious Diseases, 2018, 31, 194-198.	1.3	12
19	RESPIRE: breathing new life into bronchiectasis. European Respiratory Journal, 2018, 51, 1702444.	3.1	46

#	ARTICLE	IF	CITATIONS
20	<i>Pseudomonas aeruginosa</i> infection and exacerbations in bronchiectasis: more questions than answers. <i>European Respiratory Journal</i> , 2018, 51, 1702497.	3.1	14
21	Investigational inhaled therapies for non-CF bronchiectasis. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 139-146.	1.9	6
22	Characterization of the "Frequent Exacerbator Phenotype" in Bronchiectasis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 1410-1420.	2.5	215
23	The pharmacological treatment of bronchiectasis. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 245-258.	1.3	3
24	Design of an Activity-Based Probe for Human Neutrophil Elastase: Implementation of the Lossen Rearrangement To Induce Förster Resonance Energy Transfers. <i>Biochemistry</i> , 2018, 57, 742-752.	1.2	28
25	Infection Is Not Required for Mucoinflammatory Lung Disease in CFTR-Knockout Ferrets. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 1308-1318.	2.5	108
26	Elastase activity on sputum neutrophils correlates with severity of lung disease in cystic fibrosis. <i>European Respiratory Journal</i> , 2018, 51, 1701910.	3.1	67
27	Phosphoinositide 3-kinase $\hat{\Gamma}$ (PI3K $\hat{\Gamma}$) in respiratory disease. <i>Biochemical Society Transactions</i> , 2018, 46, 361-369.	1.6	19
28	Bronchiectasis Exacerbations Are Heart-Breaking. <i>Annals of the American Thoracic Society</i> , 2018, 15, 301-303.	1.5	7
29	Neutrophil elastase increases airway ceramide levels via upregulation of serine palmitoyltransferase. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2018, 314, L206-L214.	1.3	13
30	Circulating desmosine as a biomarker of azithromycin treatment response: a <i>post hoc</i> analysis of the COLUMBUS randomised controlled trial. <i>ERJ Open Research</i> , 2018, 4, 00136-2018.	1.1	0
31	Bronchiectasis. <i>Nature Reviews Disease Primers</i> , 2018, 4, 45.	18.1	181
32	A comprehensive approach to lung function in bronchiectasis. <i>Respiratory Medicine</i> , 2018, 145, 120-129.	1.3	46
33	Role of Inflammatory Risk Factors in the Pathogenesis of <i>Streptococcus pneumoniae</i> . <i>Frontiers in Immunology</i> , 2018, 9, 2275.	2.2	10
34	Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity. <i>Lancet</i> , The, 2018, 392, 880-890.	6.3	247
35	Bronchiectasis: Treatment decisions for pulmonary exacerbations and their prevention. <i>Respirology</i> , 2018, 23, 1006-1022.	1.3	24
36	SPLUNC1 degradation by the cystic fibrosis mucosal environment drives airway surface liquid dehydration. <i>European Respiratory Journal</i> , 2018, 52, 1800668.	3.1	28
37	"The missing ingredient" the patient perspective of health related quality of life in bronchiectasis: a qualitative study. <i>BMC Pulmonary Medicine</i> , 2018, 18, 81.	0.8	28

#	ARTICLE	IF	CITATIONS
38	Non-tuberculous mycobacterial pulmonary infections. <i>Pulmonology</i> , 2018, 24, 120-131.	1.0	30
39	The Role of the Immune Response in the Pathogenesis of Bronchiectasis. <i>BioMed Research International</i> , 2018, 2018, 1-12.	0.9	20
40	US Patient-Centered Research Priorities and Roadmap for Bronchiectasis. <i>Chest</i> , 2018, 154, 1016-1023.	0.4	14
41	The overlap between bronchiectasis and chronic airway diseases: state of the art and future directions. <i>European Respiratory Journal</i> , 2018, 52, 1800328.	3.1	138
42	Respiratory Manifestations of the Activated Phosphoinositide 3-Kinase Delta Syndrome. <i>Frontiers in Immunology</i> , 2018, 9, 338.	2.2	40
43	Bronchiectasis: an emerging global epidemic. <i>BMC Pulmonary Medicine</i> , 2018, 18, 76.	0.8	30
44	Pathogenesis, imaging and clinical characteristics of CF and non-CF bronchiectasis. <i>BMC Pulmonary Medicine</i> , 2018, 18, 79.	0.8	43
45	One Small Step for Neutrophils, One Giant Leap for Bronchiectasis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 828-830.	2.5	10
46	The Neutrophilic Response to <i>Pseudomonas</i> Damages the Airway Barrier, Promoting Infection by <i>Klebsiella pneumoniae</i> . <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2018, 59, 745-756.	1.4	10
47	The impact of acute air pollution fluctuations on bronchiectasis pulmonary exacerbation: a case-crossover analysis. <i>European Respiratory Journal</i> , 2018, 52, 1702557.	3.1	42
48	Las bronquiectasias: una enfermedad compleja y heterogénea. <i>Archivos De Bronconeumología</i> , 2019, 55, 427-433.	0.4	16
49	Antimicrobial peptides, disease severity and exacerbations in bronchiectasis. <i>Thorax</i> , 2019, 74, 835-842.	2.7	43
50	Bronchiectasis: A Complex, Heterogeneous Disease. <i>Archivos De Bronconeumología</i> , 2019, 55, 427-433.	0.4	7
51	Neutrophil elastase as a biomarker for bacterial infection in COPD. <i>Respiratory Research</i> , 2019, 20, 170.	1.4	53
52	Pregnancy Zone Protein Is Associated with Airway Infection, Neutrophil Extracellular Trap Formation, and Disease Severity in Bronchiectasis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, 992-1001.	2.5	42
53	Evaluation of active neutrophil elastase in sputum of bronchiectasis and cystic fibrosis patients: A comparison among different techniques. <i>Pulmonary Pharmacology and Therapeutics</i> , 2019, 59, 101856.	1.1	16
54	Plasma Desmosine and Abdominal Aortic Aneurysm Disease. <i>Journal of the American Heart Association</i> , 2019, 8, e013743.	1.6	22
55	Promotion of a Protease-Antiprotease Imbalance in the Airways through Chronic Vaping. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, 1337-1339.	2.5	3

#	ARTICLE	IF	CITATIONS
56	The efficacy and safety of inhaled antibiotics for the treatment of bronchiectasis in adults: a systematic review and meta-analysis. <i>Lancet Respiratory Medicine</i> , 2019, 7, 855-869.	5.2	75
57	Towards precision medicine in bronchiectasis: what is the role of neutrophilic elastase determination?. <i>European Respiratory Journal</i> , 2019, 53, 1900765.	3.1	4
58	A point-of-care neutrophil elastase activity assay identifies bronchiectasis severity, airway infection and risk of exacerbation. <i>European Respiratory Journal</i> , 2019, 53, 1900303.	3.1	50
59	Neutrophil Elastase Activity Imaging: Recent Approaches in the Design and Applications of Activity-Based Probes and Substrate-Based Probes. <i>Contrast Media and Molecular Imaging</i> , 2019, 2019, 1-12.	0.4	9
60	Airway Bacterial Load and Inhaled Antibiotic Response in Bronchiectasis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, 33-41.	2.5	70
61	Muco-Obstructive Lung Diseases. <i>New England Journal of Medicine</i> , 2019, 380, 1941-1953.	13.9	233
62	Expressions of MMP-12, TIMP-4, and Neutrophil Elastase in PBMCs and Exhaled Breath Condensate in Patients with COPD and Their Relationships with Disease Severity and Acute Exacerbations. <i>Journal of Immunology Research</i> , 2019, 2019, 1-10.	0.9	17
63	Bronchiectasis insanity: Doing the same thing over and over again and expecting different results?. <i>F1000Research</i> , 2019, 8, 293.	0.8	11
64	Bronchiectasis in severe asthma. <i>Current Opinion in Pulmonary Medicine</i> , 2019, 25, 71-78.	1.2	16
65	Personalised anti-inflammatory therapy for bronchiectasis and cystic fibrosis: selecting patients for controlled trials of neutrophil elastase inhibition. <i>ERJ Open Research</i> , 2019, 5, 00252-2018.	1.1	20
66	Prognostic Value of Frequent Exacerbations in Bronchiectasis: The Relationship With Disease Severity. <i>Archivos De Bronconeumologia</i> , 2019, 55, 81-87.	0.4	3
67	Pathophysiology, causes and genetics of paediatric and adult bronchiectasis. <i>Respirology</i> , 2019, 24, 1053-1062.	1.3	33
68	New insights into immunological responses to infection in bronchiectasis. <i>European Respiratory Journal</i> , 2019, 53, 1802395.	3.1	4
69	The biology of pulmonary exacerbations in bronchiectasis. <i>European Respiratory Review</i> , 2019, 28, 190055.	3.0	48
70	The Clinical and Research Utility of Bronchoscopy in Cystic Fibrosis. <i>Clinical Pulmonary Medicine</i> , 2019, 26, 76-81.	0.3	0
71	Bronchiectasis. <i>Chest</i> , 2019, 155, 825-833.	0.4	26
72	Microbiological Progress in Patients with Bronchial Infection with <i>Pseudomonas aeruginosa</i> Treated with Nebulised Colistin. <i>Respiration</i> , 2019, 97, 501-507.	1.2	2
73	Prognostic Value of Frequent Exacerbations in Bronchiectasis: The Relationship With Disease Severity. <i>Archivos De Bronconeumologia</i> , 2019, 55, 81-87.	0.4	37

#	ARTICLE	IF	CITATIONS
74	Distinct "Immunoallertypes" of Disease and High Frequencies of Sensitization in Non-Cystic Fibrosis Bronchiectasis. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 842-853.	2.5	57
75	Flavored e-liquids increase cytoplasmic Ca ²⁺ levels in airway epithelia. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2020, 318, L226-L241.	1.3	24
76	Cystic Fibrosis Lung Disease: An Overview. Respiratory Care, 2020, 65, 233-251.	0.8	94
77	<p>The Distribution of Alpha-1 Antitrypsin Genotypes Between Patients with COPD/Emphysema, Asthma and Bronchiectasis</p>. International Journal of COPD, 2020, Volume 15, 2827-2836.	0.9	17
78	Las bronquiectasias como enfermedad compleja. Open Respiratory Archives, 2020, 2, 226-234.	0.0	2
79	Novel Anti-Inflammatory Approaches for Cystic Fibrosis Lung Disease: Identification of Molecular Targets and Design of Innovative Therapies. Frontiers in Pharmacology, 2020, 11, 1096.	1.6	30
80	Phase 2 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis. New England Journal of Medicine, 2020, 383, 2127-2137.	13.9	158
81	The Open Challenge of in vitro Modeling Complex and Multi-Microbial Communities in Three-Dimensional Niches. Frontiers in Bioengineering and Biotechnology, 2020, 8, 539319.	2.0	5
82	Serum Desmosine Is Associated with Long-Term All-Cause and Cardiovascular Mortality in Bronchiectasis. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 897-899.	2.5	14
83	Evaluating the sensitivity and specificity of NEATstik technology compared to an activity-based immunoassay in sputum samples from participants with COPD. European Respiratory Journal, 2020, 55, 1902412.	3.1	0
84	Sputum neutrophil elastase associates with microbiota and <i>Pseudomonas aeruginosa</i> in bronchiectasis. European Respiratory Journal, 2020, 56, 2000769.	3.1	37
85	New method for rapid and dynamic quantification of elastase activity on sputum neutrophils from patients with cystic fibrosis using flow cytometry. European Respiratory Journal, 2020, 55, 1902355.	3.1	4
86	Relationship between Symptoms, Exacerbations, and Treatment Response in Bronchiectasis. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 1499-1507.	2.5	25
87	Is bronchiectasis really a disease?. European Respiratory Review, 2020, 29, 190051.	3.0	10
88	ERS International Congress, Madrid, 2019: highlights from the Airway Diseases, Asthma and COPD Assembly. ERJ Open Research, 2020, 6, 00341-2019.	1.1	3
89	Sputum neutrophil elastase in bronchiectasis: a Southern European cohort study. European Respiratory Journal, 2020, 56, 2001702.	3.1	15
90	Inhibition of neutrophil elastase prevents neutrophil extracellular trap formation and rescues mice from endotoxic shock. Biomaterials, 2020, 238, 119836.	5.7	91
91	The Impact of Hypoxia on Neutrophil Degranulation and Consequences for the Host. International Journal of Molecular Sciences, 2020, 21, 1183.	1.8	54

#	ARTICLE	IF	CITATIONS
92	Sputum trypsin-like protease activity relates to clinical outcome in cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2020, 19, 647-653.	0.3	6
93	Alpha-1 Antitrypsinâ€”A Target for MicroRNA-Based Therapeutic Development for Cystic Fibrosis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 836.	1.8	10
94	Saliva in Health and Disease. , 2020, , .		15
95	Bronchiectasis in Primary Antibody Deficiencies: A Multidisciplinary Approach. <i>Frontiers in Immunology</i> , 2020, 11, 522.	2.2	24
96	Inhaled aztreonam improves symptoms of cough and sputum production in patients with bronchiectasis: a <i>post hoc</i> analysis of the AIR-BX studies. <i>European Respiratory Journal</i> , 2020, 56, 2000608.	3.1	22
97	Paired CT Measures of Emphysema and Small Airways Disease and Lung Function and Exercise Capacity in Smokers with Radiographic Bronchiectasis. <i>Academic Radiology</i> , 2021, 28, 370-378.	1.3	10
98	A Cluster Analysis of Bronchiectasis Patients Based on the Airway Immune Profile. <i>Chest</i> , 2021, 159, 1758-1767.	0.4	18
99	Prospective Observational Study Revealing Early Pulmonary Function Changes Associated With Brigatinib Initiation. <i>Journal of Thoracic Oncology</i> , 2021, 16, 486-491.	0.5	0
100	Airway inflammation in patients with bronchiectasis. <i>Naucni Casopis Urgentne Medicine - Halo</i> 194, 2021, 27, 68-72.	0.1	0
101	A multidisciplinary approach to the management of nontuberculous mycobacterial lung disease: a clinical perspective. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 663-673.	1.0	7
102	ERS International Congress 2020: highlights from the Respiratory Infections assembly. <i>ERJ Open Research</i> , 2021, 7, 00091-2021.	1.1	1
103	Antimicrobial Resistance in Common Respiratory Pathogens of Chronic Bronchiectasis Patients: A Literature Review. <i>Antibiotics</i> , 2021, 10, 326.	1.5	8
104	Respiratory Mycoses in COPD and Bronchiectasis. <i>Mycopathologia</i> , 2021, 186, 623-638.	1.3	15
105	Personalized approaches to bronchiectasis. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 477-491.	1.0	2
106	Neutrophil extracellular trap-associated molecules: a review on their immunophysiological and inflammatory roles. <i>International Reviews of Immunology</i> , 2022, 41, 253-274.	1.5	13
107	Isolated IgG2 deficiency is an independent risk factor for exacerbations in bronchiectasis. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2022, 115, 292-297.	0.2	2
108	Proteaseâ€”Antiprotease Imbalance in Bronchiectasis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5996.	1.8	17
109	Sputum and Plasma Neutrophil Elastase in Stable Adult Patients With Cystic Fibrosis in Relation to Chronic <i>Pseudomonas Aeruginosa</i> Colonization. <i>Cureus</i> , 2021, 13, e15948.	0.2	2

#	ARTICLE	IF	CITATIONS
110	Sputum procalcitonin: a potential biomarker in stable bronchiectasis. <i>ERJ Open Research</i> , 2021, 7, 00285-2021.	1.1	0
111	T2-High Endotype and Response to Biological Treatments in Patients with Bronchiectasis. <i>Biomedicines</i> , 2021, 9, 772.	1.4	24
112	Aspergillus-Associated Endophenotypes in Bronchiectasis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2021, 42, 556-566.	0.8	6
113	Airway Clearance and Mucoactive Therapies. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2021, 42, 616-622.	0.8	2
114	Bronchiectasis Exacerbations: Definitions, Causes, and Acute Management. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2021, 42, 595-605.	0.8	6
115	<i>Pseudomonas aeruginosa</i> in Bronchiectasis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2021, 42, 587-594.	0.8	7
116	Neutrophil Elastase and Chronic Lung Disease. <i>Biomolecules</i> , 2021, 11, 1065.	1.8	68
117	Pathophysiology of Bronchiectasis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2021, 42, 499-512.	0.8	17
118	Association between Cardiorespiratory Fitness and Bronchiectasis at CT: A Long-term Population-based Study of Healthy Young Adults Aged 18â€“30 Years in the CARDIA Study. <i>Radiology</i> , 2021, 300, 190-196.	3.6	0
119	Evolution of NETosis markers and DAMPs have prognostic value in critically ill COVID-19 patients. <i>Scientific Reports</i> , 2021, 11, 15701.	1.6	56
120	Serum hepatocyte growth factor as a predictor of disease severity and future exacerbations in patients with non-cystic fibrosis bronchiectasis. <i>Respiratory Medicine</i> , 2021, 185, 106505.	1.3	2
121	Efficacy of Roflumilast in Bronchiectasis Patients with Frequent Exacerbations: A Double-Blinded, Randomized, Placebo-Controlled Pilot Clinical Trial. <i>Tuberculosis and Respiratory Diseases</i> , 2022, 85, 67-73.	0.7	4
122	The sputum microbiome and clinical outcomes in patients with bronchiectasis: a prospective observational study. <i>Lancet Respiratory Medicine</i> , 2021, 9, 885-896.	5.2	63
123	Neutrophil extracellular traps, disease severity, and antibiotic response in bronchiectasis: an international, observational, multicohort study. <i>Lancet Respiratory Medicine</i> , 2021, 9, 873-884.	5.2	99
124	Small Airway Disease and Emphysema Are Associated with Future Exacerbations in Smokers with CT-derived Bronchiectasis and COPD: Results from the COPD Gene Cohort. <i>Radiology</i> , 2021, 300, 706-714.	3.6	16
125	Prognostic utility of various multidimensional grading scales among Saudi patients with bronchiectasis. <i>Respiratory Medicine and Research</i> , 2021, 80, 100843.	0.4	0
127	C-Reactive Protein Concentration in Steady-State Bronchiectasis: Prognostic Value of Future Severe Exacerbations. Data From the Spanish Registry of Bronchiectasis (RIBRON). <i>Archivos De Bronconeumologia</i> , 2021, 57, 21-27.	0.4	30
128	Thrombocytosis during Stable State Predicts Mortality in Bronchiectasis. <i>Annals of the American Thoracic Society</i> , 2021, 18, 1316-1325.	1.5	6

#	ARTICLE	IF	CITATIONS
129	C-Reactive Protein Concentration in Steady-State Bronchiectasis: Prognostic Value of Future Severe Exacerbations. Data From the Spanish Registry of Bronchiectasis (RIBRON). Archivos De Bronconeumologia, 2021, 57, 21-27.	0.4	35
130	Comparative Analysis of Clinical Parameters and Sputum Biomarkers in Establishing the Relevance of Filamentous Fungi in Cystic Fibrosis. Frontiers in Cellular and Infection Microbiology, 2020, 10, 605241.	1.8	1
131	How do we know what works? Clinical trial end-points and quality of life assessment. , 0, , 99-132.		2
132	Airway clearance techniques, pulmonary rehabilitation and physical activity. , 0, , 331-352.		1
133	Phenotypes and endotypes. , 0, , 133-152.		1
135	Cardiovascular implications in bronchiectasis. , 2020, , 96-107.		1
136	Heterogeneity of treatment response in bronchiectasis clinical trials. European Respiratory Journal, 2022, 59, 2100777.	3.1	21
137	Therapeutic antibodies “ natural and pathological barriers and strategies to overcome them. , 2022, 233, 108022.		15
138	Cardiovascular Events during and after Bronchiectasis Exacerbations and Long-Term Mortality. Chest, 2021, , .	0.4	0
139	The Lung Microbiome during Health and Disease. International Journal of Molecular Sciences, 2021, 22, 10872.	1.8	72
140	Intermittent prophylactic antibiotics for bronchiectasis. The Cochrane Library, 0, , .	1.5	1
141	Salivary Biomarkers in Respiratory Diseases. , 2020, , 111-120.		0
142	Inflamaci3n local y sist4mica en bronquiectasias. Endotipos y biomarcadores. Open Respiratory Archives, 2020, 2, 235-241.	0.0	0
143	Management of frequently exacerbating patients. , 0, , 300-311.		0
144	Defining severe bronchiectasis. , 0, , 62-81.		0
145	Non-cystic fibrosis bronchiectasis: definition, severity and impact of pulmonary exacerbations. , 0, , 38-57.		0
146	Non-cystic fibrosis bronchiectasis: treatment and prevention of pulmonary exacerbations. , 0, , 181-198.		0
147	Future directions: the next 10 years in research. , 0, , 371-387.		0

#	ARTICLE	IF	CITATIONS
148	The emerging role of proteases in α 1-antitrypsin deficiency and beyond. ERJ Open Research, 2021, 7, 00494-2021.	1.1	5
150	Biomarcadores biológicos en las enfermedades respiratorias. Archivos De Bronconeumologia, 2022, 58, 323-333.	0.4	14
151	Intermittent prophylactic antibiotics for bronchiectasis. The Cochrane Library, 2022, 2022, CD013254.	1.5	4
152	Physiology and pathophysiology of human airway mucus. Physiological Reviews, 2022, 102, 1757-1836.	13.1	78
153	Characterization of Eosinophilic Bronchiectasis: A European Multicohort Study. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 894-902.	2.5	67
154	ERS International Congress 2021: highlights from the Respiratory Infections Assembly. ERJ Open Research, 0, , 00642-2021.	1.1	0
155	Blood-based and Imaging Biomarkers of Atherosclerosis. Cardiology in Review, 2022, Publish Ahead of Print, .	0.6	1
156	[Translated article] Biological Biomarkers in Respiratory Diseases. Archivos De Bronconeumologia, 2022, 58, T323-T333.	0.4	11
157	Neutrophil extracellular traps in chronic lung disease: implications for pathogenesis and therapy. European Respiratory Review, 2022, 31, 210241.	3.0	44
158	Future Directions in Bronchiectasis Research. Clinics in Chest Medicine, 2022, 43, 179-187.	0.8	7
159	Microbiology and the Microbiome in Bronchiectasis. Clinics in Chest Medicine, 2022, 43, 23-34.	0.8	10
160	The Pathogenesis of Bronchiectasis. Clinics in Chest Medicine, 2022, 43, 35-46.	0.8	4
161	The Effect of CFTR Modulators on Airway Infection in Cystic Fibrosis. International Journal of Molecular Sciences, 2022, 23, 3513.	1.8	23
162	Endotyping Chronic Obstructive Pulmonary Disease, Bronchiectasis, and the "Chronic Obstructive Pulmonary Disease" Bronchiectasis Association. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 417-426.	2.5	29
163	Sputum neutrophil elastase and its relation to pediatric bronchiectasis severity: A cross-sectional study. Health Science Reports, 2022, 5, e581.	0.6	4
164	Inflammation resolution in environmental pulmonary health and morbidity. Toxicology and Applied Pharmacology, 2022, 449, 116070.	1.3	10
165	Serum Fibrinogen as a Biomarker for Disease Severity and Exacerbation in Patients with Non-Cystic Fibrosis Bronchiectasis. Journal of Clinical Medicine, 2022, 11, 3948.	1.0	3
166	Pharmacokinetic/Pharmacodynamic Evaluation of the Dipeptidyl Peptidase 1 Inhibitor Brensocatib for Non-cystic Fibrosis Bronchiectasis. Clinical Pharmacokinetics, 2022, 61, 1457-1469.	1.6	7

#	ARTICLE	IF	CITATIONS
167	Bronchiectasis – A Clinical Review. <i>New England Journal of Medicine</i> , 2022, 387, 533-545.	13.9	31
168	Association between early chronic methicillin-susceptible <i>Staphylococcus aureus</i> colonization and lung function in children with cystic fibrosis. <i>Pediatric Pulmonology</i> , 0, .	1.0	0
169	Airway Inflammation in Children with Primary Ciliary Dyskinesia. <i>Annals of the American Thoracic Society</i> , 0, .	1.5	5
170	Determination of reference intervals for neutrophil granular enzymes is affected by cell isolation techniques. <i>Journal of Immunological Methods</i> , 2022, 510, 113346.	0.6	2
171	Augmentation therapy with human alpha-1-proteinase inhibitor reduces exacerbations in patient with bronchiectasis and alpha-1-antitrypsin deficiency. <i>Respiratory Medicine Case Reports</i> , 2022, 39, 101740.	0.2	0
172	Point-of-Care Monitoring of Respiratory Diseases Using Lateral Flow Assay and CMOS Camera Reader. <i>IEEE Journal of Translational Engineering in Health and Medicine</i> , 2022, 10, 1-8.	2.2	4
173	An optimized method of extracting and quantifying active Neutrophil serine proteases from human whole blood cells. <i>PLoS ONE</i> , 2022, 17, e0272575.	1.1	4
174	Bronchiectasis and obstructive lung diseases in primary antibody deficiencies and beyond: update on management and pathomechanisms. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2022, 22, 335-342.	1.1	1
175	Pathophysiology of Chronic Bronchial Infection in Bronchiectasis. <i>Archivos De Bronconeumologia</i> , 2023, 59, 101-108.	0.4	10
176	Novel inhibitors and activity-based probes targeting serine proteases. <i>Frontiers in Chemistry</i> , 0, 10, .	1.8	1
177	Monitoring disease progression in childhood bronchiectasis. <i>Frontiers in Pediatrics</i> , 0, 10, .	0.9	2
178	Neutrophil Elastase in the Pathogenesis of Chronic Obstructive Pulmonary Disease: A Review. <i>Current Respiratory Medicine Reviews</i> , 2023, 19, 29-35.	0.1	0
179	Environmental and Infectious Causes of Bronchiectasis. <i>Respiratory Medicine</i> , 2022, , 85-115.	0.1	1
180	Peripheral Neutrophil-to-Lymphocyte Ratio in Bronchiectasis: A Marker of Disease Severity. <i>Biomolecules</i> , 2022, 12, 1399.	1.8	4
182	Bronchial Gene Expression Alterations Associated with Radiographic Bronchiectasis. <i>European Respiratory Journal</i> , 0, , 2200120.	3.1	1
184	Emerging Approaches to Monitor and Modify Care in the era of CFTR Modulators. <i>Clinics in Chest Medicine</i> , 2022, 43, 631-646.	0.8	1
185	Bronchiectasis exacerbation: a narrative review of causes, risk factors, management and prevention. <i>Annals of Translational Medicine</i> , 2023, 11, 25-25.	0.7	6
186	Inhibition of neutrophil elastase prevents cigarette smoke exposure-induced formation of neutrophil extracellular traps and improves lung function in a mouse model of chronic obstructive pulmonary disease. <i>International Immunopharmacology</i> , 2023, 114, 109537.	1.7	3

#	ARTICLE	IF	CITATIONS
187	Cardiovascular and cerebrovascular-associated mortality in patients with preceding bronchiectasis exacerbation. <i>Therapeutic Advances in Respiratory Disease</i> , 2022, 16, 175346662211442.	1.0	1
188	Pro-resolving and pro-inflammatory fatty acid-derived mediators in sputum of stable state bronchiectasis patients. <i>Respiratory Research</i> , 2022, 23, .	1.4	1
189	Bacteriophage: A new therapeutic player to combat neutrophilic inflammation in chronic airway diseases. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	0
190	Insights into Personalised Medicine in Bronchiectasis. <i>Journal of Personalized Medicine</i> , 2023, 13, 133.	1.1	1
192	ERS International congress 2022: highlights from the respiratory infections assembly. <i>ERJ Open Research</i> , 0, , 00628-2022.	1.1	0
193	Neutrophil Extracellular Traps in Airway Diseases: Pathological Roles and Therapeutic Implications. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5034.	1.8	11
194	Towards development of evidence to inform recommendations for the evaluation and management of bronchiectasis. <i>Respiratory Medicine</i> , 2023, 211, 107217.	1.3	2
195	Benefit-risk assessment of brensocatib for treatment of non-cystic fibrosis bronchiectasis. <i>ERJ Open Research</i> , 2023, 9, 00695-2022.	1.1	0
196	Endotypes in bronchiectasis: moving towards precision medicine. A narrative review. <i>Pulmonology</i> , 2023, 29, 505-517.	1.0	5
197	The role of precision medicine in bronchiectasis: emerging data and clinical implications. <i>Expert Review of Respiratory Medicine</i> , 2023, 17, 279-293.	1.0	0
202	Bronchiectasis: from orphan disease to precision medicine. , 2023, , 150-164.		0